FDA approves Eli Lilly's tirzepatide for weight loss The injection helped certain patients in a recent study lose nearly 60 pounds The Food and Drug Administration (FDA) approved Eli Lilly's drug tirzepatide Wednesday for the treatment of obesity
Study Results In a one-month trial of liposomal glutathione (GSH), levels of glutathione markers increased significantly after just two weeks, by up to 40% in blood and 28% in plasma
GLP-1 receptor agonists (GLP-1 RAs) have been used to treat type 2 diabetes (T2D) for more than 15 years including Novo Nordisk products such as semaglutide and liraglutide that have been on the market for more than 10 years
This article examines the clinical evidence regarding seizure risk with Wegovy, reviews recognised neurological side effects, and provides guidance on safety monitoring in line with UK regulatory standards from the MHRA, NICE, and current pharmacovigilance data
The key to confidently and compliantly using your HSA for weight loss injections is the involvement of medical professionals